Business Context and Reporting Period
Company: Achieve Life Sciences, Inc. (ACHV)
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2025
Event: Entry into a Material Definitive Agreement for a public equity offering.
Key Financial Metrics and Offering Details
- Securities Issued: 15,000,000 shares of common stock and accompanying warrants to purchase up to 15,000,000 additional shares.
- Public Offering Price: $3.00 per share and accompanying warrant.
- Estimated Net Proceeds: Approximately $41.3 million (after underwriting discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 2,250,000 shares and/or warrants.
- Warrant Terms:
- Exercise Price: $3.00 per share (or $2.999 for Pre-Funded Warrants).
- Expiration: Fifth anniversary of issuance (Pre-Funded Warrants have no expiration).
- Ownership Limitation: 9.99% of outstanding common stock immediately post-exercise.
- Expected Closing Date: June 30, 2025.
Material Changes
This filing represents a material change in the company's capital structure through the execution of an underwriting agreement. The filing does not provide comparative financial performance metrics (revenue, profit, cash flow) for the current period versus prior periods, as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
- Use of Proceeds: The filing states the offering is being made but does not explicitly detail the specific allocation of proceeds in the text provided, other than noting the net amount.
- Forward-Looking Statements: The company cautions that actual results may differ materially from expectations regarding the closing date and net proceeds.
- Risks: Risks include those identified in the company's Form 10-Q for the three months ended March 31, 2025, and the prospectus supplement. Adverse impacts on operations could significantly affect the stock price.
- Contingencies: Closing is subject to the satisfaction of customary conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds upon completion of the offering.
- Confirm whether the underwriters exercise the 30-day over-allotment option for an additional 2,250,000 shares/warrants.
- Review the specific "Use of Proceeds" section in the related Prospectus Supplement (referenced but not detailed in this 8-K text).
- Monitor the impact of the 15,000,000 new shares and potential warrant exercises on existing shareholder dilution.
- Check the Form 10-Q filed on May 13, 2025, for the most recent financial position prior to this capital raise.